Rescue Pharmacotherapy for Obstructive Sleep Apnea

(RescOSA Trial)

Overseen By David Andrew Wellman, MD

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Brigham and Women's Hospital

Must be taking: Acetazolamide, Atomoxetine, Trazodone

Must not be taking: Opioids, Benzodiazepines, SSRIs, SNRIs

Disqualifiers: Central sleep apnea, COPD, Pregnancy, others

Compensation: Varies

Number of Visits: 1

Duration: 1 night

70 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests additional drug treatments for people with obstructive sleep apnea (OSA) who haven't found enough relief from current therapies, such as jaw adjustment devices or nerve stimulation. The goal is to assist those who continue to struggle with OSA despite using these devices. Participants will try one of three different drugs based on their specific sleep apnea traits: acetazolamide (a diuretic medication), a combination of atomoxetine and eszopiclone, or trazodone. This trial suits those who still experience frequent sleep disruptions despite trying the usual devices. As a Phase 1, Phase 2 trial, the research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, such as those that stimulate or depress breathing (like opioids and benzodiazepines) and SSRIs/SNRIs. If you are on any of these, you would need to stop them to participate in the trial.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Previous studies have shown that trazodone holds promise in treating obstructive sleep apnea (OSA). It can reduce breathing problems during sleep by increasing the arousal threshold without interfering with the muscles in the upper airway, indicating good safety.

Research on the combination of atomoxetine and eszopiclone shows mixed results. Atomoxetine might lower the arousal threshold, potentially making it difficult for some individuals with sleep issues to tolerate. However, eszopiclone, a sleep aid, is known for its safety in treating insomnia and helps individuals stay asleep through the night.

Acetazolamide has been studied for OSA and was found to reduce the Apnea-Hypopnea Index (a measure of sleep apnea severity) by about 37.7%. It also helps lower high blood pressure, common in OSA patients, indicating it is generally well-tolerated.

Overall, while each treatment has its own safety profile, they all show potential for helping OSA patients who have not responded to other treatments. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for obstructive sleep apnea because they target specific traits of the condition, offering a personalized approach. Trazodone is used to increase the arousal threshold, potentially reducing awakenings during sleep. The combination of atomoxetine and eszopiclone targets pharyngeal muscle responsiveness, potentially improving airway stability. Acetazolamide works by addressing increased loop gain, which is a measure of the stability of breathing control. Unlike standard treatments like CPAP machines, which can be cumbersome and uncomfortable, these medications offer a tailored, potentially more comfortable option that addresses the underlying traits of sleep apnea.

What evidence suggests that this trial's treatments could be effective for obstructive sleep apnea?

In this trial, participants will receive one of several treatments based on their specific sleep apnea traits. Research has shown that trazodone, which some participants may receive, can significantly reduce breathing interruptions in people with obstructive sleep apnea (OSA), lowering the apnea-hypopnea index (AHI) from 38.7 events per hour with a placebo to 28.5 events per hour.

For those with weak throat muscles, the combination of atomoxetine with eszopiclone, another treatment option in this trial, has shown promise. Studies suggest that this combination can greatly reduce OSA severity by helping keep the airway open during sleep.

Acetazolamide, also tested in this trial, has been found to improve oxygen levels in the blood during sleep. It helps people with sensitive breathing control, a common issue in OSA, breathe more regularly.

Each of these treatments targets different aspects of OSA, offering personalized options for those who don't respond to traditional therapies like the mandibular advancement device or hypoglossal nerve stimulation. ^{1 6 7 8 9}

Are You a Good Fit for This Trial?

This trial is for individuals with persistent obstructive sleep apnea (OSA) who haven't found relief through mandibular advancement device (MAD) or hypoglossal nerve stimulation (HGNS). Participants must have a residual AHI of ≥15 events/hr despite these treatments. People with certain medical conditions, including severe liver or kidney issues, specific heart problems, glaucoma, and those on conflicting medications like SSRIs/SNRIs are excluded.

Inclusion Criteria

My sleep apnea treatment with a device hasn't reduced my symptoms enough.

Exclusion Criteria

I do not have any unstable major health conditions.

I do not have heart, liver, kidney issues, glaucoma, priapism, and I'm not pregnant/breastfeeding or have mental health issues that trazodone could worsen.

I have a sleep disorder like restless legs, narcolepsy, or unusual behaviors during sleep.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive pharmacotherapy based on their specific OSA endotype, including drugs such as acetazolamide, atomoxetine-plus-eszopiclone, or trazodone

1 night

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Acetazolamide
• Atomoxetine and eszopiclone
• Placebo
• Trazodone

Trial Overview The study tests whether adding one of several drugs—acetazolamide, atomoxetine-plus-eszopiclone, trazodone—or a placebo can improve OSA in patients unresponsive to MAD or HGNS. Each drug targets different physiological traits contributing to OSA such as high loop gain or low arousal threshold.

How Is the Trial Designed?

Group I: Interventional arm Active Control 3 Interventions

This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).

Group II: Placebo Placebo Group 1 Intervention

This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).

Who Is Running the Clinical Trial?

Brigham and Women's Hospital

Lead Sponsor

Trials

1,694

Recruited

14,790,000+

Published Research Related to This Trial

Acetazolamide, temazepam, zolpidem, and zaleplon are supported by available data as effective and safe options for improving sleep at high altitudes, based on a review of pharmacologic interventions.

Diazepam should be avoided at high altitude due to the risk of hypoventilation, while other common sleep medications like eszopiclone and diphenhydramine, though not specifically studied at altitude, are likely safe based on their known effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Which medications are safe and effective for improving sleep at high altitude? Luks, AM.[2018]

A systematic review of 58 randomized controlled trials involving 1710 patients found that while some drugs, like acetazolamide, showed a small reduction in the apnoea-hypopnoea index (AHI), the overall efficacy of pharmacotherapy for obstructive sleep apnoea (OSA) remains limited.

Despite some drugs demonstrating potential benefits, the effects were generally small and not clinically significant, indicating that there is currently insufficient evidence to recommend any pharmacotherapy for OSA, and no large-scale phase-III trials have been conducted.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of pharmacotherapy for OSA in adults: A systematic review and network meta-analysis. Gaisl, T., Haile, SR., Thiel, S., et al.[2020]

Eszopiclone (Lunesta) is an FDA-approved short-acting hypnotic agent effective for treating insomnia, with a duration of effect lasting up to 6 hours, which helps improve sleep maintenance and reduce nocturnal awakenings.

Clinical trials involving over 2700 adult and elderly subjects demonstrated that eszopiclone is effective for both sleep onset and maintenance, and it showed enhanced efficacy when combined with fluoxetine in patients with insomnia and major depressive disorder.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Eszopiclone: esopiclone, estorra, S-zopiclone, zopiclone--Sepracor. [2018]

The combination of atomoxetine and trazodone (Ato-Trazo) significantly reduced the apnea-hypopnea index in patients with obstructive sleep apnea (OSA), indicating improved severity of the condition, with a reduction from 18.2 to 7.4 events per hour (P = .024).

Unlike previous treatments, Ato-Trazo did not lower the arousal threshold, suggesting it may be better tolerated by patients, although it worsened self-reported sleep quality and further studies are needed to optimize dosage and identify the best patient subgroups.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway. Corser, B., Eves, E., Warren-McCormick, J., et al.[2023]

Treatment-emergent central sleep apnoea (TECSA) can occur in about 8% of patients using CPAP for obstructive sleep apnoea, but it often resolves on its own in 60% to 80% of cases.

In a case study of a 74-year-old man, adding acetazolamide to CPAP treatment effectively resolved his TECSA, suggesting that acetazolamide may be a beneficial adjunct therapy for patients with significant symptoms.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment-emergent central sleep apnoea managed by CPAP with adjunctive acetazolamide: A case report. Kwok, CT., Wong, KC., Kwok, CL., et al.[2022]

In a study involving 45 patients with obstructive sleep apnea (OSA), acetazolamide significantly improved oxygen levels and reduced breathing disturbances at high altitudes compared to a placebo, indicating its potential as an alternative treatment when CPAP is not used.

Acetazolamide not only enhanced nocturnal oxygen saturation and reduced apnea/hypopnea indices but also improved sleep quality and prevented high blood pressure during altitude exposure, suggesting it stimulates ventilation effectively in OSA patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial. Nussbaumer-Ochsner, Y., Latshang, TD., Ulrich, S., et al.[2017]

Eszopiclone, approved in the U.S. in 2004, is an effective treatment for insomnia and has been studied for its use in patients with conditions like obstructive sleep apnea, highlighting its versatility in managing sleep disorders.

The review discusses safety concerns, including its effects on taste (dysgeusia) and potential impacts on memory and cognitive functions, which are important considerations for its use in patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Eszopiclone: an update on its use in insomnia. Owen, RT.[2017]

Acetazolamide has been established as the most effective medication for treating sleep apnea syndrome (SAS), outperforming other pharmacological options.

Other therapeutic approaches for SAS, including nasal CPAP, dental appliances, and surgeries, have not shown satisfactory effects when acetazolamide is not included in the treatment plan.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Drug therapy for sleep apnea syndrome]. Takahashi, Y., Shimizu, T.[2013]

Insomnia is a common issue for patients with chronic obstructive pulmonary disease (COPD), and treating it effectively is crucial for their overall care.

Traditional benzodiazepines may worsen respiratory function in COPD patients, so alternative treatments like non-benzodiazepine receptor agonists (e.g., eszopiclone, zolpidem) and melatonin receptor agonists (e.g., ramelteon) are being considered for safer management of insomnia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Roth, T.[2009]

In a study involving 10 participants with severe obstructive sleep apnea (OSA), the combination of atomoxetine with solifenacin improved upper airway function, reducing the frequency of obstructive apneas and increasing oxygen levels during sleep, although it did not significantly change overall OSA severity compared to placebo.

The combination of atomoxetine with biperiden reduced next-day sleepiness, indicating potential benefits for alertness, but overall, both combinations had modest effects compared to previous findings with atomoxetine and oxybutynin, suggesting that the choice of antimuscarinic agent can influence treatment outcomes for OSA.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity. Aishah, A., Lim, R., Sands, SA., et al.[2023]

Acetazolamide significantly improves sleep apnea at high altitudes by reducing the Apnea-Hypopnea Index (AHI) and increasing nocturnal oxygenation, particularly in healthy trekkers compared to those with obstructive sleep apnea (OSA).

A daily dose of 250 mg of acetazolamide may be as effective as higher doses for healthy individuals, suggesting a potential optimal therapeutic dose for treating sleep apnea in high-altitude conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis. Liu, HM., Chiang, IJ., Kuo, KN., et al.[2018]

In a study of 18 adults with obstructive sleep apnea (OSA), the combination of atomoxetine and trazodone significantly reduced the apnea-hypopnea index (AHI) and improved other sleep parameters compared to placebo, indicating better respiratory function during sleep.

The A-T combination also led to fewer apneas, less oxygen desaturation, and reduced respiratory arousals, suggesting it could be a viable alternative treatment for patients who struggle with standard OSA therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The effects of atomoxetine and trazodone combination on obstructive sleep apnea and sleep microstructure: A double-blind randomized clinical trial study. Shahbazi, M., Heidari, R., Tafakhori, A., et al.[2023]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7768933/

Acetazolamide for OSA and Central Sleep Apnea Furthermore, acetazolamide improved oxygen saturation nadir by +4.4% (95% CI, 2.3 to 6.5; I2 = 63%; no evidence of effect modification; very low QoE) and ...

2. clinicaltrials.gov clinicaltrials.gov/study/NCT05804084

Study Details | NCT05804084 | Patient-centered and ... The goal of this study is to test if acetazolamide can improve sleep apnea, neurocognitive function and quality of life in adults with OSA, and to assess how it ...

3. sciencedirect.com sciencedirect.com/science/article/abs/pii/S1389945723001405

Acute and long-term effects of acetazolamide in presumed ... The effect of acetazolamide in reducing residual sleep apnea lasts at least 3 months. •. The apnea-hypopnea index during non-rapid eye movement sleep is a ...

4. publications.ersnet.org publications.ersnet.org/content/erj/60/suppl66/3872

Effectiveness of acetazolamide in patients with moderate ... Acetazolamide (AZT) has shown potential in the correction of central sleep apnea traits. Aim: To investigate the treatment effect of acetazolamide in patients ...

5. jcsm.aasm.org jcsm.aasm.org/doi/10.5664/jcsm.9116

The role of acetazolamide in sleep apnea at sea level Acetazolamide reduces blood pressure and sleep-disordered breathing in patients with hypertension and obstructive sleep apnea: a randomized controlled trial.

6. clinicaltrials.gov clinicaltrials.gov/study/NCT05616260

Acetazolamide for Obstructive Sleep Apnea to Improve ... Recent data suggest, that acetazolamide may help OSA patients to not choke in their sleep and lower their blood pressure.

7. jcsm.aasm.org jcsm.aasm.org/doi/10.5664/jcsm.6968

Acetazolamide Reduces Blood Pressure and Sleep ... AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.

8. clinicaltrials.ucsd.edu clinicaltrials.ucsd.edu/trial/NCT05616260

Acetazolamide for Obstructive Sleep Apnea to Improve Heart ... Recent data suggest, that acetazolamide may help OSA patients to not choke in their sleep and lower their blood pressure.

9. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC5941979/

The effect of acetazolamide on sleep apnea at high altitude Acetazolamide is more beneficial in healthy participants than in OSA patients, and a 250 mg daily dose may be as effective as higher daily doses for healthy ...